Seventh Annual CreatorIQ Study Finds Creator Marketing Delivers Record ROI Amid Infrastructure and AI Complexities September 30, 2026 New data from CreatorIQ's seventh annual global State of Creator Marketing report shows nearly half of brands now earn 3x or greater ROI from creators, and budgets have increased 33% YoY, while AI-driven complexity and systems integration emerge as the industry's biggest challenges to operating at scale.
Manchester City hierarchy must also be punished if guilty, says former FA chief September 30, 2026 Manchester City chiefs must face personal punishments if the findings that they orchestrated almost £1bn of secret payments to the club are upheld, according to former Football Association boss Mark Palios. City say they intend to appeal the decision made by an independent commission that all but one of more than 100 charges brought by [...]
Zilch leaning towards London IPO as UK fintech calls in bankers September 30, 2026 UK fintech Zilch is leaning towards a public debut on the London Stock Exchange as it kickstarts plans for a potential $2bn listing as soon as next year. The payments firm, founded in London in 2018, views London as the favoured venue for a listing, likely to take place in the second half of 2027 [...]
Studio behind Danny Dyer and Hugh Jackman films calls in administrators September 30, 2026 A British film studio founded by an ex-Lionsgate boss has folded into administration just a few years after taking $150m in start-up financing. True Brit Entertainment, which was founded by former Lionsgate UK chief executive Zygi Kamasa, appointed administrators on Monday, according to filings. The distributor was set up in 2023 hoping to boost the [...]
Lime targets commuters with ‘more affordable’ cycle to work scheme September 30, 2026 Lime is making its e-bikes cheaper for workers through the Cycle to Work scheme as the ubiquitous green operator steps up its push for a bigger wedge of London’s daily commute. Workers will be able to pay for an annual Lime subscription through salary sacrifice, cutting the cost by as much as 47 per cent [...]
Amentum Joint Venture Secures Preferred Position for Major UK Nuclear Contract September 30, 2026 United Kingdom nuclear site operator Sellafield Ltd has selected an Amentum (NYSE: AMTM) joint venture as preferred supplier for an asset care and asset creation program valued at up to $2.78 billion (£2.1 billion). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930996796/en/ Under the Projects and Asset Care Execution (PACE) framework contract, [...]
Greggs puts 740 jobs at risk as baker braces for worse inflation September 30, 2026 Greggs has announced a shakeup of its manufacturing processes which could lead to the closure of four factories and cost 740 jobs, as the baker warns of “greater inflationary pressures” across its business. The sausage roll seller told shareholders on Wednesday that it is consulting on a move to consolidate its manufacturing operations, which would [...]
The Debate: Should you be allowed to text in sick? September 30, 2026 The government's back-to-work tsar wants you to call, but is texting in sick a non-issue? We hear the case for and against in the Debate.
Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026 September 30, 2026 Almirall’s scientific programme at EADV 2026 showcases advances in critical skin diseases, including atopic dermatitis, psoriasis and actinic keratosis, through more than 20 abstracts, including a late-breaking abstracts, alongside two expert-led symposia and an interactive industry AD hub session. New clinical data show consistent efficacy and effectiveness in atopic dermatitis treatment across body regions with lebrikizumab, including high-impact areas such as the face and neck1,2, while late-breaking ADlong results highlight sustained improvements in skin signs and itch with up to five years of treatment3. Final two-year data from the POSITIVE clinical study demonstrate the benefits on patient overall well-being and quality of life during tildrakizumab treatment4,5, and further data show evidence in patients with high disease burden and previous biologic treatment6,7. Almirall’s commitment to medical dermatology is reflected by its Gold Sponsorship of EADV 2026 and the launch of the ‘Face It’-campaign to raise awareness of the burden of atopic dermatitis with face and neck involvement, addressing the broader impact of skin diseases on patients.
£250m lawsuit against crypto firm Binance grows with 1000 new investors September 30, 2026 A thousand new UK-based retail investors have been added to a group legal claim against crypto trading platform Binace and its founder, alleging they were sold high-risk, complex products that did not have regulatory authorisation from the financial watchdog. There are now approximately 2,700 claimants in the case in England and Wales, with the total [...]